Protein nanomatrixes and method of production
Patent 5308620 Issued on May 3, 1994. Estimated Expiration Date: 
October 13, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
October 13, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same Process for the preparaton of dispersible colloidal systems of a substance in the form of nanocapsules Patent #: 5049322 InventorAssigneeApplicationNo. 959560 filed on 10/13/1992US Classes:424/484, Matrices424/486, Synthetic polymer424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)424/499, Contains proteins or derivative or polysaccharides or derivative516/77, Aqueous continuous liquid phase and discontinuous phase primarily solid (e.g., water based suspensions, dispersions, or certain sols*, of natural or synthetic ester-wax, beeswax, carnauba wax; or latex dispersion)516/922COLLOID SYSTEMS HAVING SPECIFIED PARTICLE SIZE, RANGE, OR DISTRIBUTION (E.G., BIMODAL PARTICLE DISTRIBUTION)ExaminersPrimary: Kishore, G. S.Attorney, Agent or FirmInternational ClassA61K 009/14AbstractThe present invention is a novel method of producing a unique device of stable porous and membraneless nanomatrixes for carrying medication for in vivo administration. The present invention method produces the device of stable nanomatrixes by mixing a first type of protein which is hemoglobin, a second type of protein which is albumin, and a solution containing an organic solvent which is an alcohol, where the weight ratio of the first and second type of proteins is within the range of approximately 92&#b1;5 to 8&#b1;5. This results in a turbid suspension of monodispersed nanomatrixes which are typically larger than 1 micron but less than 4 microns in diameter and stable against aggregation and re-solubilization in hypotonic saline for at least 24 hours. An additional solution containing a biologically active substance may be added before or after the solution containing an organic solvent, such that the biologically active substance is entrapped within or bound on the surfaces of the nanomatrixes.Other References
Field of SearchMatricesParticulate form (e.g., powders, granules, beads, microcapsules, and pellets) Containing proteins and derivatives Synthetic polymer Contains proteins or derivative or polysaccharides or derivative Synthesis of peptides Separation or purification Solvent extraction Alcohol Physical treatment Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI Produced by or extracted from animal tissue | |
